SHH

Across TCGA pan-cancer cohorts, SHH Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SHH data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SHH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHH expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

LUSC, ACC, and SKCM are the cancer types where SHH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.279	0.742	.032	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	III,IV	0.353	0.729	.043	3	view →
COAD	DFS	Median	II,III,IV	1.000	0.747	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SHH–LUSC (OS)

Open the LUSC breakdown →